HUTCHMED
Biotechnology Research
Building a global science-focused biopharma from an established base in China.
First mover in China’s biotech industry
HUTCHMED (Nasdaq/AIM: HCM; HKEX:13) is an innovative biopharmaceutical company committed, over the past twenty years, to the discovery and global development of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Established in 2000, we are one of the first movers in China’s biotech industry. Our vision to create new and better treatment options for patients around the world has remained unchanged.
Visit Our WebsiteFirst ever Chinese biotech company to bring an oncology drug from discovery, all the way through to unconditional approval, and onto commercialization
In 2018, we made history as the first ever Chinese biopharma company to receive unconditional approval in China for an in-house developed oncology drug with fruquintinib, a medicine for the treatment of metastatic colorectal cancer. Two years later, in 2020 our second oncology drug, surufatinib, to treat neuroendocrine tumors was approved. In June 2021, our third in-house discovered oncology drug, savolitinib, gained approval, becoming a first-in-class selective MET inhibitor in China.
Our ProductsGlobal-facing Drug Discovery Platform Generating Multiple Waves of Innovation
At HUTCHMED, we design all of our drugs to have global potential, with optimized characteristics such as high potency and low off-target toxicity, rendering better safety and pharmacokinetic profiles for patients. Our world class in-house discovery engine has created a pipeline of 10 clinical-stage novel drug candidates to date that are currently in over 40 ongoing clinical trials in China and globally.
Our PipelineCompany photos
Similar pages
Stock
HCM
NASDAQ
20 minutes delay
$17.26
-0.63 (-3.522%)
- Open
- 17.53
- Low
- 16.98
- High
- 17.735
Data from Refinitiv
See more info on